What is PT-141?
PT-141 (Bremelanotide) is a melanocortin receptor agonist FDA-approved as Vyleesi for hypoactive sexual desire disorder in premenopausal women. Unlike PDE5 inhibitors, it works through the central nervous system to enhance sexual arousal and desire. Derived from Melanotan II research.
Key Benefits & Mechanisms
Enhances sexual desire and arousal
Works through CNS (not vascular)
FDA-approved for HSDD
Effective for both men and women
Does not require sexual stimulation to work
Alternative to PDE5 inhibitors
Rapid onset of action
Research Summary
PT-141 has robust clinical evidence including multiple Phase III trials. FDA-approved in 2019. Unique mechanism of action through melanocortin-4 receptors in the brain. Well-characterized safety and efficacy profile.